Yersinia pestis

Cell death is essential to your health − an immunologist explains when cells decide to die with a bang or take their quiet leave

Retrieved on: 
수요일, 10월 4, 2023
Apoptosis, Tissue, Infection, Endometriosis, DNA, Maintenance, Yersinia enterocolitica, Cell death, DSM-IV codes, Neoplasm, Black, COVID-19, Fever, Finger, Survival, Cancer, The, Black Death, Research, Cell, Lupus, Yersinia pestis, Uterus, Pain, Pandemic, Protein, Patient, Swelling, Immune system, Bacteria, Immunodeficiency, Health, Death, Yersinia, Virus, Red, Skin, Vaccine, Pharmaceutical industry

While death may seem passive, an unfortunate ending that just “happens,” the death of your cells is often extremely purposeful and strategic.

Key Points: 
  • While death may seem passive, an unfortunate ending that just “happens,” the death of your cells is often extremely purposeful and strategic.
  • The intricate details of how and why cells die can have significant effects on your overall health.
  • My own research explores how immune cells switch between different types of programmed death in scenarios like cancer or injury.

Quietly exiting: silent cell death

    • Regardless of the timeline, the death of old and damaged cells and their replacement with new cells is a normal and important bodily process.
    • Silent cell death, or apoptosis, is described as silent because these cells die without causing an inflammatory reaction.
    • Apoptosis is an active process involving many proteins and switches within the cell.
    • Sometimes cells can detect that their own functions are failing and turn on executioner proteins that chop up their own DNA, and they quietly die by apoptosis.
    • Whether it’s for development or maintenance, your cells are quietly exiting to keep your body happy and healthy.

Going out with a bang: inflammatory cell death

    • This inflammatory cell death is typically triggered by bacteria, viruses or stress.
    • Rather than quietly shutting down, cells undergoing inflammatory cell death will make themselves burst, or lyse, killing themselves and exploding inflammatory messengers as they go.
    • These infections are rarely fatal because your immune cells can aggressively eliminate the pathogen’s niche by inducing inflammatory cell death.
    • The virus behind the COVID-19 pandemic also causes a lot of inflammatory cell death.
    • Researchers are still studying the role of inflammatory cell death in COVID-19 infection, and understanding this delicate balance can help improve treatments.

T2 Biosystems Receives FDA 510(k) Clearance for the T2Biothreat Panel

Retrieved on: 
화요일, 9월 19, 2023
Ochsner Medical Center, ASPR, Burkholderia pseudomallei, Plague, Emergency, Biomedical Advanced Research and Development Authority, CBRN, Office of Inspector General, U.S. Department of Health and Human Services, HHS, Administration for Strategic Preparedness and Response, Public, Infection, Tularemia, Public Health Service Act, Unitary state, Typhus, Biosafety, Glanders, Yersinia pestis, Government, Melioidosis, Bacillus anthracis, Burkholderia mallei, Development, Administration, Disaster, MRIGlobal, Francisella tularensis, Biological warfare, Public health, Patient, Rickettsia prowazekii, Bacillus, Mortality, FDA, Anthrax, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, BARDA, Food, Pharmaceutical industry, Vaccine, Medical device

LEXINGTON, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the T2Biothreat™ Panel.

Key Points: 
  • LEXINGTON, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the T2Biothreat™ Panel.
  • The FDA 510(k) clearance allows the company to immediately begin marketing and selling the T2Biothreat Panel in the U.S. market.
  • The U.S. clinical evaluation to support the FDA 510(k) submission included testing of the T2Biothreat Panel at MRIGlobal, a Biosafety Level 3 laboratory specializing in biothreat pathogens, and Ochsner Medical Center.
  • The T2Biothreat Panel is able to detect the six aforementioned biothreat pathogens within four hours providing clinicians with the needed information to appropriately treat infected patients.

ContraFect Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
월요일, 8월 14, 2023
Exercise, Infection, PK, MIC, XDR, Hemolysis, IV, S. aureus, Methicillin-resistant Staphylococcus aureus, Daptomycin, CMC, MRSA, Pharmacokinetics, ASM, G&A, Osteomyelitis, Acinetobacter, Yersinia pestis, Gram-negative bacteria, Cons, Staphylococcus aureus, Klebsiella pneumoniae, Trial of the century, Chemistry, Pseudomonas aeruginosa, NPN, MDR, Patient, Meropenem, Campaign, R, Urinary tract infection, Research, Safety, IND, Amikacin, ChromeOS, Knee, Peptide, Staphylococcus, Pharmaceutical industry, Vaccine, Klebsiella, Pseudomonas

“We remain on track to file an IND for our second program, CF-370, which is our engineered lysin targeting Gram-negative pathogens, in the third quarter.

Key Points: 
  • “We remain on track to file an IND for our second program, CF-370, which is our engineered lysin targeting Gram-negative pathogens, in the third quarter.
  • Research and development (R&D) expenses were $4.9 million for the second quarter of 2023 compared to $16.8 million in the comparable period in 2022.
  • General and administrative (G&A) expenses were $3.1 million for the second quarter of 2023 compared to $3.3 million in the comparable period in 2022.
  • As of June 30, 2023, ContraFect had cash and cash equivalents of $14.4 million.

New Study in Chinese Medicine and Culture Reveals History and Modern-Day Relevance of Plague

Retrieved on: 
수요일, 7월 12, 2023
Human, Food, Prevalence, Research, History, Yersinia pestis, Nankai University, Epidemic, Literature, Zoonosis, Animal, Pithing, City, Bacteria, Culture, Health, Environment, Plague, Medicine, Tea

TIANJIN, China, July 12, 2023 /PRNewswire/ -- Plague, known as Shu Yi in China, is an infectious zoonotic disease caused by the bacteria Yersinia pestis that is transmitted by rodents and marmots. The term Shu Yi was believed to be coined by Chinese scholars in the late 19th century after the arrival of western medicine and considered a modern medical concept. There has been much research on the history of this epidemic and its impact on Chinese demography and society. However not much is known about the concept of Shu Yi and how it came to being.

Key Points: 
  • The term Shu Yi was believed to be coined by Chinese scholars in the late 19th century after the arrival of western medicine and considered a modern medical concept.
  • There has been much research on the history of this epidemic and its impact on Chinese demography and society.
  • In a study published in Chinese Medicine and Culture , Prof. XinZhong Yu and Prof. Yu Tian from Nankai University, China, sought to investigate the conceptual history of Shu Yi.
  • Through an exhaustive search of scientific and historical literature, the researchers traced its origins, prevalence, popularization, and relevance into modern-day life.

ContraFect Data Presentations at ASM Microbe 2023 Demonstrate the Power of the Company’s Proprietary Platform to Discover New Agents Targeting Antibiotic-Resistant Gram-negative Pathogens

Retrieved on: 
화요일, 6월 20, 2023
MIC, XDR, Hemolysis, S. aureus, Methicillin-resistant Staphylococcus aureus, Daptomycin, MRSA, Cancer, ASM, Osteomyelitis, Acinetobacter, Yersinia pestis, Gram-negative bacteria, Staphylococcus aureus, Cons, Klebsiella pneumoniae, Pseudomonas aeruginosa, NPN, Knee, ECCMID, Animal, Lower respiratory tract infection, Patient, Ventilator-associated pneumonia, Meropenem, Fungal infection, Bacteria, Campaign, Amikacin, Food, Peptide, Staphylococcus, Vaccine, Yersinia, Burkholderia, MD, Klebsiella, Pseudomonas

“The data presented at ASM Microbe is quite powerful.

Key Points: 
  • “The data presented at ASM Microbe is quite powerful.
  • Both dose regimens of CF-370 in addition to amikacin significantly reduced bacteria counts compared to all other treatment groups (p≤0.0001).
  • The results of this study reproduce the efficacy seen in previously released data presented at ECCMID 2023 further demonstrating the bactericidal power of CF-370 against XDR strains of Gram-negative pathogens.
  • The results of this study reinforce previously released data demonstrating the power of both CF-296 and exebacase when delivered locally in the rabbit osteomyelitis model.

ContraFect to Present New Data Demonstrating the Potential Efficacy of Its Engineered Lysins Against Antibiotic-Resistant Pathogens at ASM Microbe 2023

Retrieved on: 
목요일, 6월 8, 2023
Klebsiella pneumoniae, Campaign, ASM, XDR, Potent, Conference, Yersinia pestis, Peptide, Vaccine, Klebsiella

YONKERS, N.Y., June 08, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announces that the Company has been selected to present four posters at the ASM Microbe Conference to be held in Houston, Texas from June 15-19, 2023.

Key Points: 
  • YONKERS, N.Y., June 08, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announces that the Company has been selected to present four posters at the ASM Microbe Conference to be held in Houston, Texas from June 15-19, 2023.
  • The data being presented will feature CF-370 demonstrating efficacious activity in a neutropenic rabbit pneumonia model against an extensively-drug-resistant (XDR) strain of Klebsiella pneumoniae (K. pneumoniae).
  • ASM Microbe 2023 Poster Presentation Details:
    Engineered Lysins with Potent In Vitro Activity Against Burkholderia spp.
  • and Yersinia pestis

T2 Biosystems Announces FDA 510(k) Submission for the T2Biothreat Panel

Retrieved on: 
화요일, 5월 23, 2023
Burkholderia pseudomallei, Plague, Biomedical Advanced Research and Development Authority, U.S. Department of Defense Strategy for Operating in Cyberspace, Public, Infection, Office of Inspector General, U.S. Department of Health and Human Services, Administration for Strategic Preparedness and Response, Tularemia, Typhus, Glanders, Yersinia pestis, Melioidosis, Bacillus anthracis, Burkholderia mallei, Administration, Development, Francisella tularensis, Biological warfare, Public health, Patient, Rickettsia prowazekii, Bacillus, Mortality, Health, FDA, Anthrax, Regulation of tobacco by the U.S. Food and Drug Administration, BARDA, Food, Vaccine, Pharmaceutical industry

LEXINGTON, Mass., May 23, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the Company’s T2Biothreat™ Panel.

Key Points: 
  • LEXINGTON, Mass., May 23, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the Company’s T2Biothreat™ Panel.
  • The FDA submission follows the recently completed U.S. clinical evaluation that demonstrated very high sensitivity and specificity, and included 350 contrived positive samples and over 470 negative blood samples from both healthy and febrile subjects.
  • "This FDA submission marks an important milestone in our commitment to protect Americans from the threat of deliberate or naturally occurring outbreaks of biothreat pathogens,” stated John Sperzel, Chairman and CEO of T2 Biosystems.
  • The T2Biothreat Panel is able to detect the aforementioned biothreat pathogens within 4 hours and provide clinicians with the needed information to appropriately treat infected patients.

SAB Biotherapeutics Announces First Publication of Promising Nonclinical Data for SAB-183 Against Pneumonic Plague in the Journal Antibodies

Retrieved on: 
금요일, 5월 12, 2023
SAB, United States Army Medical Research Institute of Infectious Diseases, Antigen, Plague, Partnership, SARS-CoV-2, Public, Infection, Phagocytosis, Mutation, Yersinia pestis, Immunotherapy, Pneumonic plague, Bubonic plague, F1, Viral, Mouse, Search for the Higgs boson, LcrV, Vaccine, MD, Antibody, TC

SIOUX FALLS, S.D., May 12, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human immunoglobulin (hIgG) antibodies, also known as fully-human polyclonal antibodies, without the need for human donors, today announced the publication of nonclinical data in the medical journal Antibodies. The data are from a study conducted in collaboration with the United States Army Medical Research Institute of Infectious Diseases (USAMRID) highlighting that fully-human immunoglobulins derived from Tc bovines can protect mice from Yersinia pestis, a Tier 1 select bacterial biothreat agent that can rapidly cause fatal infections and is associated with pneumonic plague as well as bubonic plague.

Key Points: 
  • The article, “ Polyclonal antibodies derived from transchromosomic bovines vaccinated with the recombinant F1-V vaccine increase bacterial opsonization in vitro and protect mice from pneumonic plague ,” was published online in the 10th anniversary special issue of Antibodies.
  • Y. pestis is a major biothreat due to its capacity for aerosol dissemination and its highly contagious nature in the pneumonic form.
  • “These promising nonclinical data generated in partnership with USAMRID offer evidence that SAB-183 may provide broad coverage against plague and other mutating infections,” said Tom Luke, MD, Head of Research for SAB Biotherapeutics.
  • This publication marks the first study data that have been announced for SAB-183.

T2 Biosystems Announces Positive Results upon Completion of U.S. Clinical Evaluation for the T2Biothreat Panel

Retrieved on: 
월요일, 2월 13, 2023
Administration, Francisella tularensis, Anthrax, Office of Inspector General, U.S. Department of Health and Human Services, Tularemia, Burkholderia mallei, Food and Drug Administration, Development, Plague, Patient, Biosafety, BARDA, Clinical trial, Yersinia pestis, Glanders, Food, Health, Melioidosis, Bacillus anthracis, Burkholderia pseudomallei, Mortality, U.S. Department of Defense Strategy for Operating in Cyberspace, MRIGlobal, Typhus, Biological warfare, Biomedical Advanced Research and Development Authority, FDA, Public health, Bacillus, Public, Infection, Administration for Strategic Preparedness and Response, Vaccine, Pharmaceutical industry, Rickettsia

LEXINGTON, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced positive results upon completion of the U.S. clinical evaluation for the T2Biothreat™ Panel.

Key Points: 
  • LEXINGTON, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced positive results upon completion of the U.S. clinical evaluation for the T2Biothreat™ Panel.
  • “We are extremely pleased with the results of the clinical evaluation.
  • Rapid detection of these pathogens is essential to getting infected patients on the appropriate antimicrobial therapy and improving clinical outcomes.
  • The results of the clinical trial demonstrated very high sensitivity and specificity across all six targets.

T2 Biosystems Announces BARDA Exercise of Contract Option 3 Valued at $3.7 Million

Retrieved on: 
목요일, 9월 29, 2022
Adoption, Francisella tularensis, Development, Biomedical Advanced Research and Development Authority, Department, Burkholderia mallei, Burkholderia pseudomallei, Assistant, FDA, Food, Office of Inspector General, U.S. Department of Health and Human Services, North Carolina Department of Health and Human Services, BARDA, U.S. Securities and Exchange Commission, Bacillus anthracis, Contract, Health, Private Securities Litigation Reform Act, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, Patient, Regulation of tobacco by the U.S. Food and Drug Administration, CEO, Office of the Assistant Secretary for Preparedness and Response, Yersinia pestis, Diagnosis, NASDAQ, GLOBE, SEC, Rickettsia prowazekii, Bloodstream infections, Failure, Pharmaceutical industry, Vaccine

The total potential BARDA funding if all contract options are exercised is $62.0 million, reflecting a reduction in the scope of work under contract option 3.

Key Points: 
  • The total potential BARDA funding if all contract options are exercised is $62.0 million, reflecting a reduction in the scope of work under contract option 3.
  • T2 Biosystems products include the T2Dx Instrument, T2Bacteria Panel, T2Candida Panel, T2Resistance Panel, and T2SARS-CoV-2 Panel and are powered by the Companys proprietary T2 Magnetic Resonance (T2MR) technology.
  • Thus, no one should assume that the Companys silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements.
  • These forward-looking statements should not be relied upon as representing the companys views as of any date subsequent to the date of this press release.